Long-term treatment of early Alzheimer’s disease with donanemab
Vincenzo Solfrizzi, Bruno P. Imbimbo
openaire +2 more sources
Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes. [PDF]
Shir D +10 more
europepmc +1 more source
Before the bolus: why anti-amyloid therapy must become part of every stroke code. [PDF]
Khaliq AS, Khan K.
europepmc +1 more source
Variability of cognitive changes after donanemab treatment
openaire +2 more sources
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain. [PDF]
Bjørnholm KD +14 more
europepmc +1 more source
Beyond the Cochrane review: Re-evaluating anti-amyloid therapy in Alzheimer's disease. [PDF]
Bernath MM +5 more
europepmc +1 more source
Donanemab therapy in Alzheimer's disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement. [PDF]
Tang L, Xu Y, Zhao H.
europepmc +1 more source
Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab. [PDF]
Guizzaro L +10 more
europepmc +1 more source

